Virus-like particles: designing an effective AIDS vaccine (Q36602273)

15 August 2017

1 reference

title

Virus-like particles: designing an effective AIDS vaccine (English)

1 reference

15 August 2017

Kelly R Young

1

1 reference

15 August 2017

Sean P McBurney

series ordinal

2

1 reference

15 August 2017

Lukena U Karkhanis

series ordinal

3

1 reference

15 August 2017

Ted M Ross

series ordinal

4

1 reference

15 August 2017

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

40

1 reference

15 August 2017

1

1 reference

15 August 2017

98-117

1 reference

Complete nucleotide sequences of functional clones of the AIDS virus

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Nucleotide sequence of the AIDS virus, LAV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Tenth anniversary perspectives on AIDS. HIV: between past and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV-1 gag proteins: diverse functions in the virus life cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Defining HIV-1 protease substrate selectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Mechanistic aspects of HIV-1 reverse transcription initiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV integrase structure and function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV integrase, a brief overview from chemistry to therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV integrase as a target for antiviral chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Structural interactions between chemokine receptors, gp120 Env and CD4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV-1 envelope determinants for cell tropism and chemokine receptor use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Antibody neutralization of HIV-1 and the potential for vaccine design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV-1 regulatory proteins: targets for novel drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

The ins and outs of HIV Rev.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Nef: agent of cell subversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Structure--function relationships in HIV-1 Nef.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Viral persistence: HIV's strategies of immune system evasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV-1 VPR modulates cell cycle G2/M transition through an alternative cellular mechanism other than the classic mitotic checkpoints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Insights into the biology of HIV-1 viral protein R.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Slipping through the door: HIV entry into the nucleus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV accessory proteins: multifunctional components of a complex system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

The epidemiology of AIDS: current status and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Sequential determination of viral load and phenotype in human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

The immunopathogenesis of human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Zidovudine in the management of primary HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

The influence of lymphocyte counts and disease progression on circulating and inducible anti-HIV-1 cytotoxic T-cell activity in HIV-1-infected subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Determinants of virological response to antiretroviral therapy: implications for long-term strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV-1 Tat-based vaccines: from basic science to clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Neutralizing antibodies against HIV -- back in the major leagues?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Strategies for an HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

A review of vaccines for HIV prevention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

New hope for an AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

A Phase II Study of Two HIV Type 1 Envelope Vaccines, Comparing Their Immunogenicity in Populations at Risk for Acquiring HIV Type 1 Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Human Immunodeficiency Virus Type 1 Env with an Intersubunit Disulfide Bond Engages Coreceptors but Requires Bond Reduction after Engagement To Induce Fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Effects of HIV Type 1 Envelope Glycoprotein Proteolytic Processing on Antigenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Stepwise deletion of the HIV type 1 glycoprotein 41 N terminus leads to an increasing export of microvesicles containing uncleaved Env glycoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Defining the Protective Antibody Response for HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Vaccine technology: looking to the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Live attenuated AIDS viruses as vaccines: promise or peril?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Protective immunity induced by live attenuated simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Mechanisms of protection against simian immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Simian immunodeficiency virus as a model of human HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Non-human primate models for AIDS vaccine research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Efficacy of a SHIV 89.6 proviral DNA vaccine against mucosal SIVmac239 challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

A new approach to AIDS research and prevention: the use of gene-mutated HIV-1/SIV chimeric viruses for anti-HIV-1 live-attenuated vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Construction of human immunodeficiency virus 1/simian immunodeficiency virus strain mac chimeric viruses having vpr and/or nef of different parental origins and their in vitro and in vivo replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Using SHIVs to develop an anti-HIV-1 live-attenuated vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Live attenuated HIV vaccines: pitfalls and prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Highly attenuated SIVmac142 is immunogenic but does not protect against SIVmac251 challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Replication, Immunogenicity, and Protective Properties of Live-Attenuated Simian Immunodeficiency Viruses Expressing Interleukin-4 or Interferon-γ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Macaques infected long-term with attenuated simian immunodeficiency virus (SIVmac) remain resistant to wild-type challenge, despite declining cytotoxic T lymphocyte responses to an immunodominant epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Single-cycle immunodeficiency viruses provide strategies for uncoupling in vivo expression levels from viral replicative capacity and for mimicking live-attenuated SIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Simian immunodeficiency virus promoter exchange results in a highly attenuated strain that protects against uncloned challenge virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Importance of the intracytoplasmic domain of the simian immunodeficiency virus (SIV) envelope glycoprotein for pathogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Importance of the nef gene for maintenance of high virus loads and for development of AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Immune mechanisms associated with protection from vaginal SIV challenge in rhesus monkeys infected with virulence-attenuated SHIV 89.6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Protective immune responses induced by a non-pathogenic simian/human immunodeficiency virus (SHIV) against a challenge of a pathogenic SHIV in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Infection of macaque monkeys with a chimeric human and simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

The chimpanzee and other non-human-primate models in HIV-1 vaccine research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Protective immunity of gene-deleted SHIVs having an HIV-1 Env against challenge infection with a gene-intact SHIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Protection against late-onset AIDS in macaques prophylactically immunized with a live simian HIV vaccine was dependent on persistence of the vaccine virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Augmentation of antigen-specific cytokine responses in the early phase of vaccination with a live-attenuated simian/human immunodeficiency chimeric virus expressing IFN-gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Chimeric SHIV that causes CD4+ T cell loss and AIDS in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Characterization of a neutralization-escape variant of SHIVKU-1, a virus that causes acquired immune deficiency syndrome in pig-tailed macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Chimpanzee models for human disease and immunobiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Long-term symptomless HIV-1 infection in recipients of blood products from a single donor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Identification of a new recipient in the Sydney Blood Bank Cohort: a long-term HIV type 1-infected seroindeterminate individual

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

The Sydney Blood Bank Cohort: a case-control study using a transfused HIV-1 seronegative group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Effect of long-term infection with nef-defective attenuated HIV type 1 on CD4+ and CD8+ T lymphocytes: increased CD45RO+CD4+ T lymphocytes and limited activation of CD8+ T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Morphopoietic determinants of HIV-1 Gag particles assembled in baculovirus-infected cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Production and characterization of simian--human immunodeficiency virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

A multivalent HIV-vaccine: development of a plasmid DNA for the expression of HIV envelope glycoproteins with hypervariable V3-loop domains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Construction of an artificial immunogen, a candidate DNA vaccine encoding multiple CTL epitopes of HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

DNA mucosal HIV vaccine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Evaluation in rabbits of different anti-SHIV vaccine strategies based on DNA/fowlpox priming and virus-like particle boosting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Virus-like particle and DNA-based candidate AIDS vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV. Envelope's letters boxed into shape.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Host cell glycosylation of viral glycoproteins--a battlefield for host defence and viral resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV-1 antibody--debris or virion?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

gp120: Biologic aspects of structural features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

The antigenic structure of the HIV gp120 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Comparative analysis using a mouse model of the immunogenicity of artificial VLP and attenuated Salmonella strain carrying a DNA-vaccine encoding HIV-1 polyepitope CTL-immunogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Preparation and induction of immune responses by a DNA AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Studies in macaques on cross-clade T cell responses elicited by a DNA/MVA AIDS vaccine, better conservation of CD8 than CD4 T cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Elicitation of immunity to HIV type 1 Gag is determined by Gag structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Further evidence for hexagonal organization of HIV gag protein in prebudding assemblies and immature virus-like particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Assembly and release of SIV env proteins with full-length or truncated cytoplasmic domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Immunogenicity of Full Length and Truncated SIV Envelope Proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Strong augment effect of IL-12 expression plasmid on the induction of HIV-specific cytotoxic T lymphocyte activity by a peptide vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

In vitro and in vivo responses to interleukin 12 are maintained until the late SIV infection stage but lost during AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

HIV vaccines: the Uganda experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

Construction and characterization of replication-competent simian immunodeficiency virus vectors that express gamma interferon.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

7 January 2021

Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

7 January 2021

Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

7 January 2021

A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

7 January 2021

Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

7 January 2021

Simian immunodeficiency virus DNA vaccine trial in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

7 January 2021

Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.024

7 January 2021

10.1016/J.YMETH.2006.05.024

Identifiers

DOI

1 reference

15 August 2017

1 reference